Foundation / Corporation
Alzheimer's Drug Discovery Foundation (ADDF)
11/09/18 5:00 PM EST Receipt
Grants to USA, Canada, and International postdoctoral fellows, clinicians, and researchers working in nonprofit organizations, universities, academic medical centers, and biotechnology companies for research on the prevention of Alzheimer's and related dementias. LOIs are due April 13.
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods, supplements, and drugs. However, high-powered studies are needed—ideally with dose, duration, and responder profiles—in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.
Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding drug discovery programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.
GrantWatch ID#: 182777
-$50,000 - $100,000 for epidemiological analyses based on scope of research
-Up to $3 million based on stage and scope of research.
Average grant duration is one year for epidemiological analyses. Average duration varies (multi-year) for clinical trials.
Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:
-Academic medical centers and universities or nonprofits
-Biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.
For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
It is highly recommended that you access the ADDF Funding Portal to begin the application process well in advance of any deadlines. Please note, new applicants should allow 1-2 business days for registration.
Letters of Intent and Full Proposals must be received by 5:00 PM EST on the deadline date.
-Letter of Intent: January 19, 2018
-Invited Full Proposal: February 9, 2018
-Letter of Intent: April 13, 2018
-Invited Full Proposal: May 11, 2018
-Letter of Intent: July 13, 2018
-Invited Full Proposal: August 10, 2018
-Letter of Intent: October 12, 2018
-Invited Full Proposal: November 9, 2018
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
For program-related inquiries, please contact:
Yuko Hara, PhD, Acting Director, Aging & Alzheimer's Prevention
For application submission inquiries, please contact:
Grants and Mission-Related Investments Team
Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904
New York, NY 10019
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.